A Study of LY3537031 in Healthy Participants

Lilly

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: Placebo

Drug: LY3537031

Study type

Interventional

Funder types

Industry

Identifiers

NCT04648865

17756 (Other Identifier)

J2S-MC-GZMA (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to evaluate the safety and tolerability of LY3537031 in healthy participants. The blood tests will be performed to check how much LY3537031 gets into the bloodstream, how long the body takes to eliminate it and how body handles LY3537031. Each participant will receive a single dose of LY3537031 or placebo. The study will last up to approximately 71 days for each participant, including screening.

Enrollment

40 patients

Sex

All

Ages

20 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Are male or female not of childbearing potential
Have a body mass index (BMI) between 19 and 35 kilograms per square meter (kg/m²) and a body weight ≥ 54 kilograms (kg)
Have blood pressure, pulse rate, blood and urine laboratory test results that are acceptable for the study
Have veins suitable for blood sampling

Exclusion criteria

Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
Have a diagnosis or history of cancer or malignant disease within 5 years
Have been treated with prescription and over-the-counter medications that promote weight loss within 3 months prior to screening
Show clinical evidence of syphilis, HIV, hepatitis C, or hepatitis B, and/or test positive
Have undergone any form of bariatric surgery
Have previously completed or withdrawn from this study
Are currently participating in or completed a clinical trial within the last 3 months
Regularly use known drugs of abuse or with positive drug results
Smoke >10 cigarettes per day or the equivalent, or are unable or unwilling to refrain from nicotine during CRU admission